Not medical advice. A record of published research and our assessments of it. The limits

A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2

A Master Protocol to Investigate the Efficacy and Safety of Orforglipron Once Daily in Participants With Hypertension and Obesity or Overweight: Randomized, Double-Blind, Placebo-Controlled Trials (ATTAIN-HYPERTENSION)
NCT06952530 on ClinicalTrials.gov

Status: Active not recruitingResults none
Why it is watched: non-weight indication: cardiovascular
Who it enrolls: age 18 Years to no upper limit; no BMI minimum stated; conditions: Hypertension
Interventions: Orforglipron; Placebo
Conditions: Hypertension
Phase and size: Phase 3 · 487 participants
Dates: Start 2025-04-30
Primary completion 2027-09
Sponsor: Eli Lilly and Company (Industry)
Last checked: Sep 13, 2026

01Endpoints

What the trial will measure

Change from Baseline in office Systolic Blood Pressure (SBP)Baseline to Week 36

02Eligibility

Who can take part

Inclusion Criteria: * refer to the GZPL master protocol study for screening eligibility. Exclusion Criteria: * refer to the GZPL master protocol study for screening eligibility.

03Change log

Registry changes

No changes recorded since the trial was added.